At what times of day should regular (short‑acting) insulin and NPH (intermediate‑acting) insulin be administered in a twice‑daily schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of NPH and Regular Insulin Administration in a Twice‑Daily Schedule

Administer NPH insulin in the morning (before breakfast) and at bedtime, with regular insulin given 30 minutes before breakfast and 30 minutes before dinner. This schedule aligns NPH's intermediate action with daytime and overnight basal needs while allowing regular insulin's delayed onset to match postprandial glucose excursions. 1

Morning Dose (Before Breakfast)

  • NPH insulin should be injected in the morning to provide daytime basal coverage, with its peak action occurring 4–6 hours post‑injection to coincide with midday glucose demands. 1
  • Regular insulin should be administered 30 minutes before breakfast to allow adequate time for onset, ensuring peak insulin action aligns with the postprandial glucose rise. 2, 3
  • Although a 5‑minute pre‑meal interval for regular insulin is feasible in well‑controlled patients, a 30‑minute interval remains the traditional standard to optimize postprandial glucose control. 2

Evening Dose (Before Dinner and Bedtime)

  • Regular insulin should be given 30 minutes before dinner to cover the evening meal, following the same pharmacokinetic rationale as the morning dose. 2, 3
  • NPH insulin should be administered at bedtime rather than before dinner to provide overnight basal coverage and reduce the risk of nocturnal hypoglycemia. 4
  • Bedtime NPH administration results in superior fasting glucose control compared with morning‑only NPH, achieving lower fasting plasma glucose (4.6 vs. 8.6 mmol/L) and improved 24‑hour glycemic profiles. 4

Rationale for Timing

NPH Insulin Pharmacodynamics

  • NPH has an onset of 1–2 hours, peak action at 4–6 hours, and duration of 12–16 hours, making twice‑daily dosing necessary to maintain 24‑hour basal coverage. 1
  • Morning NPH covers daytime basal needs and the lunch period, while bedtime NPH suppresses overnight hepatic glucose production and controls fasting glucose. 1, 4

Regular Insulin Pharmacodynamics

  • Regular insulin has an onset of 30–60 minutes, peak at 2–4 hours, and duration of 6–8 hours, requiring pre‑meal administration to synchronize with meal‑related glucose excursions. 2, 3
  • The 30‑minute pre‑meal interval allows regular insulin to begin acting as glucose absorption from the meal commences, preventing postprandial hyperglycemia. 2

Alternative Regimens and Considerations

Rapid‑Acting Insulin Analogues (Lispro, Aspart, Glulisine)

  • If using rapid‑acting insulin analogues instead of regular insulin, administer 0–15 minutes before meals (ideally immediately before eating) due to their faster onset (10–15 minutes) and shorter duration (3–5 hours). 3, 5, 6
  • Rapid‑acting analogues provide greater mealtime flexibility and reduce the risk of delayed hypoglycemia compared with regular insulin. 3, 6

NPH Mixed with Rapid‑Acting Insulin

  • When mixing NPH with rapid‑acting insulin (e.g., lispro) at breakfast and dinner, inject the mixture within 15 minutes before the meal to optimize both basal and prandial coverage. 3, 6
  • A typical mixing ratio is 70% lispro / 30% NPH at breakfast, 60% lispro / 40% NPH at lunch, and 80% lispro / 20% NPH at dinner, with bedtime NPH given separately. 3

Bedtime vs. Morning NPH for Type 2 Diabetes

  • In patients with type 2 diabetes and overt fasting hyperglycemia, bedtime NPH is superior to morning NPH for achieving fasting glucose targets (4.6 vs. 8.6 mmol/L) and overall glycemic control (HbA1c 5.81% vs. 6.23%). 4
  • Bedtime NPH increases basal metabolic clearance of glucose (103.5 vs. 63.5 mL/m²/min) without altering hepatic glucose output, resulting in improved basal insulinemia. 4

Practical Dosing Algorithm

Step 1: Calculate Total Daily NPH Dose

  • For insulin‑naïve patients, start with 0.1–0.2 units/kg/day total NPH, divided into two doses. 1
  • For patients on once‑daily NPH, split the total dose into two‑thirds in the morning and one‑third at bedtime. 1

Step 2: Calculate Regular Insulin Dose

  • Begin with 4 units of regular insulin before breakfast and dinner, or use 10% of the total daily insulin dose as the starting prandial dose. 1
  • Alternatively, calculate using an insulin‑to‑carbohydrate ratio of 1 unit per 10–15 g carbohydrate for regular insulin (500 ÷ total daily dose). 1

Step 3: Titration Protocol

  • NPH titration:
    • Increase morning NPH by 2 units every 3 days if pre‑lunch glucose is 140–179 mg/dL, or by 4 units every 3 days if ≥180 mg/dL. 1
    • Increase bedtime NPH by 2 units every 3 days if fasting glucose is 140–179 mg/dL, or by 4 units every 3 days if ≥180 mg/dL. 1
  • Regular insulin titration:
    • Increase each meal dose by 1–2 units every 3 days based on 2‑hour postprandial glucose, targeting <180 mg/dL. 1

Monitoring Requirements

  • Fasting glucose measured daily to guide bedtime NPH adjustments. 1, 4
  • Pre‑lunch glucose to assess morning NPH adequacy. 1
  • Pre‑dinner glucose to evaluate daytime basal coverage. 1
  • 2‑hour postprandial glucose after breakfast and dinner to titrate regular insulin doses. 1, 2
  • Bedtime glucose to ensure overnight basal coverage is adequate. 1

Common Pitfalls to Avoid

  • Do not administer bedtime NPH before dinner, as this increases the risk of nocturnal hypoglycemia due to peak insulin action occurring during sleep. 4
  • Do not inject regular insulin immediately before meals without allowing the 30‑minute interval, as this can result in postprandial hyperglycemia followed by delayed hypoglycemia. 2
  • Avoid mixing NPH with regular insulin in the same syringe unless using a premixed formulation, as this can alter the pharmacokinetics of both insulins. 6
  • Do not use rapid‑acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk. 1
  • Never discontinue basal insulin entirely in type 1 diabetes, even when hypoglycemia occurs, to prevent diabetic ketoacidosis. 1

Special Populations

Type 1 Diabetes

  • NPH combined with regular insulin requires four injections daily (morning NPH + regular before breakfast, regular before lunch, regular before dinner, bedtime NPH) to achieve adequate basal‑bolus coverage. 3, 5
  • Alternatively, use NPH four times daily (before each meal and at bedtime) combined with rapid‑acting insulin at meals for more intensive basal coverage. 5

Type 2 Diabetes

  • Bedtime NPH alone (without morning NPH) may be sufficient when combined with oral agents, providing overnight basal coverage while endogenous insulin handles daytime needs. 4
  • If fasting glucose remains elevated on bedtime NPH alone, add morning NPH to provide daytime basal support. 1, 4

Steroid‑Induced Hyperglycemia

  • Morning NPH is specifically recommended to match the pharmacokinetic profile of daily glucocorticoid therapy, with peak insulin action aligning with the steroid‑induced glucose surge 4–8 hours post‑dose. 1
  • Increase NPH dose by 40–60% above baseline requirements when initiating high‑dose glucocorticoids. 1

Transition to Long‑Acting Basal Analogues

  • When converting from twice‑daily NPH to once‑daily insulin glargine, use 80% of the total daily NPH dose administered at bedtime or dinnertime. 7
  • When converting from once‑daily bedtime NPH to glargine, use a 1:1 unit‑for‑unit conversion. 7
  • Glargine provides more stable 24‑hour basal coverage with lower hypoglycemia risk compared with NPH, eliminating the need for twice‑daily dosing. 5, 6

References

1
Guideline

Management of Steroid-Induced Hyperglycemia with NPH Insulin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Research

Morning versus bedtime isophane insulin in type 2 (non-insulin dependent) diabetes mellitus.

Diabetic medicine : a journal of the British Diabetic Association, 1992

6
Research

EADSG Guidelines: Insulin Therapy in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018

7
Guideline

Guidelines for Converting NPH Insulin to Insulin Glargine (Lantus)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the recommended NPH doses and correction scale for a Type 3c (Total Parenteral Nutrition) admitted patient with influenza on continuous tube feeding (TF), who is insulin sensitive and currently requires 13 units of NPH (Neutral Protamine Hagedorn) plus 29 units of short-acting insulin during the day and 18 units of NPH plus 12 units of short-acting insulin overnight?
In a patient on 9 units daily of NPH insulin whose serum creatinine has risen from 1.07 mg/dL (eGFR ≈ 87 mL/min) to 1.52 mg/dL (eGFR ≈ 57 mL/min), what should the NPH insulin dose be adjusted to?
What is the recommended fasting time prior to insulin injection for a patient with diabetes?
What are the doses of regular insulin for Tristin?
What should be the morning and evening NPH (Novolin N (NPH insulin)) insulin doses and correction scale for a patient with type 2 diabetes mellitus (T2DM) on a norepinephrine (Levophed (norepinephrine)) drip and hydrocortisone (Cortef (hydrocortisone)) 25 mg every 8 hours, with impaired renal function (creatinine 1.14, glomerular filtration rate (GFR) 70), who received continuous renal replacement therapy (CRRT) until yesterday and is scheduled for dialysis today, and has been experiencing hyperglycemia (blood glucose 320-350 mg/dL) despite receiving 30 units of NPH insulin overnight and an additional 17 units of short-acting insulin?
When should alternative α1‑adrenergic blockers be used instead of tamsulosin in men with benign prostatic hyperplasia?
What oral antibiotic regimen is recommended for an adult with acute mastoiditis in the Philippines after initial intravenous therapy?
In a hemodynamically stable adult with bilateral pulmonary embolism on an intravenous heparin infusion, can I discontinue the heparin and transition to apixaban (Eliquis)?
In a patient who has cleared Helicobacter pylori and has no high‑risk gastrointestinal disease, what is the best way to taper dexlansoprazole (Dexilant) 30 mg—every other day with famotidine (Pepcid) on off days or abrupt discontinuation and switch to famotidine?
Which α1‑blocker can be used for benign prostatic hyperplasia urinary symptoms in patients with chronic kidney disease or end‑stage renal disease without dose adjustment?
What intra‑abdominal pressure is recommended for robotic versus conventional laparoscopic abdominal surgery in adult patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question